Sign inJoin waitlistJoin the waitlist

Jairam Krishnamurthy

Associate Professor · Univ of Utah Sch of Med

Credentials: · · · · · · · · · ·

History

Univ of Utah Sch of Med
Present
University of Nebraska Medical Center College of Medicine
Present

Hematology and Medical Oncology
University of Nebraska Medical Center
2018–2021
All India Institute of Medical Sciences
2013–2018
All India Institute of Medical Sciences
2009–2013
CHI Health Creighton University Medical Center
2006–2009
The Carle Illinois College of Medicine
2005–2006
ALL INDIA INST OF MED SCI, ANSARI NAGAR, NEW DELHI, DELHI
2001–2005

Research

Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2022 · 759 citations
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2020 · 711 citations
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2024 · 560 citations

Pavankumar Tandra
12 papers
Anthony Elias
6 papers
CD
Chau Dang
6 papers
Doreen Agnese
6 papers
Erica Stringer-Reasor
6 papers
Harold Burstein
6 papers
HS
Hatem Soliman
6 papers
Hope Rugo
6 papers
Jame Abraham
6 papers
Janice Lyons
6 papers
Jessica Young
6 papers
JM
Joanne Mortimer
6 papers

Clinical trials

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Site PI · Recruiting · Phase 2
Eli Lilly and Company
2026–2029
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
Site PI · Unknown · Phase 2
Academic and Community Cancer Research United
2020–2025